Abstract
A proteasome-dependent proteolytic pathway serves important functions in cell cycle control and transcriptional regulation; however, its pathophysiological role in cardiovascular diseases is still unclear. We have recently obtained evidence that proteasome inhibitors are capable of preventing the development of deoxycorticosterone acetate (DOCA)-salt-induced hypertension or hypertrophy and of ischemic acute renal failure (ARF). Beneficial effects of the proteasome inhibitors were accompanied by a decrease in endothelin-1 (ET-1) content in the aorta and kidney of DOCA-salt and ischemic ARF animals, respectively. In addition, there is evidence showing that the reduction of nuclear factor-kB (NF-kB) activation is involved in the mechanisms for suppressive effects of proteasome inhibitors on ET-1 gene transcription and the consequent decrease in ET-1 mRNA expression in the cultured vascular endothelial cells. These findings suggest that a proteasome-dependent proteolytic pathway has a crucial role in the pathogenesis of ET-1-related cardiovascular diseases, probably through the activation of NF-kB, and also that the use of proteasome inhibitors may be a novel approach to the treatment of cardiovascular diseases.
Keywords: proteasome, endothelin-1, hypertension, hypertrophy, acute renal failure
Current Vascular Pharmacology
Title: Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Volume: 1 Issue: 1
Author(s): M. Takaoka, M. Ohkita and Y. Matsumura
Affiliation:
Keywords: proteasome, endothelin-1, hypertension, hypertrophy, acute renal failure
Abstract: A proteasome-dependent proteolytic pathway serves important functions in cell cycle control and transcriptional regulation; however, its pathophysiological role in cardiovascular diseases is still unclear. We have recently obtained evidence that proteasome inhibitors are capable of preventing the development of deoxycorticosterone acetate (DOCA)-salt-induced hypertension or hypertrophy and of ischemic acute renal failure (ARF). Beneficial effects of the proteasome inhibitors were accompanied by a decrease in endothelin-1 (ET-1) content in the aorta and kidney of DOCA-salt and ischemic ARF animals, respectively. In addition, there is evidence showing that the reduction of nuclear factor-kB (NF-kB) activation is involved in the mechanisms for suppressive effects of proteasome inhibitors on ET-1 gene transcription and the consequent decrease in ET-1 mRNA expression in the cultured vascular endothelial cells. These findings suggest that a proteasome-dependent proteolytic pathway has a crucial role in the pathogenesis of ET-1-related cardiovascular diseases, probably through the activation of NF-kB, and also that the use of proteasome inhibitors may be a novel approach to the treatment of cardiovascular diseases.
Export Options
About this article
Cite this article as:
Takaoka M., Ohkita M. and Matsumura Y., Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases, Current Vascular Pharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570161033386637
DOI https://dx.doi.org/10.2174/1570161033386637 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Polyphenolic Compounds from Solanum torvum on Plasma Lipid Peroxidation, Superoxide anion and Cytochrome P450 2E1 in Human Liver Microsomes
Medicinal Chemistry Precision Medicine in the Renin-Angiotensin System: Therapeutic Targets and Biological Variability
Current Drug Targets Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction
Current Hypertension Reviews Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Premature Cardiovascular Disease in Women with Lupus and Relationship to Disease Severity
Current Women`s Health Reviews Platelet Function and Signaling in Diabetes Mellitus
Current Vascular Pharmacology Isolated Anosmia as a Presentation of COVID-19: An Experience in a Referral Hospital
Infectious Disorders - Drug Targets Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors
Current Pharmaceutical Design Use of microRNAs as Anti-Atherosclerosis
Mini-Reviews in Medicinal Chemistry G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Roles for Connexins in Hypertension
Current Hypertension Reviews Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Biochemical and Molecular Basis of Insulin Resistance
Current Protein & Peptide Science RNAi in Clinical Studies
Current Medicinal Chemistry Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction?
Current Hypertension Reviews The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design